ArticleTropical medicine and infectious disease2025
Prevalence and Screening Rates of Hepatitis B and Hepatitis C Infections in Adult Patients with Solitary Organ Tumors.
Article in Tropical medicine and infectious disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) remain significant global public health issues despite advances in their diagnosis and treatment. Our country is in a medium endemic region for HBV. Reactivation can occur during or after immunosuppressive therapy. Therefore, screening patients before treatment is crucial to prevent reactivation. However, pretreatment screening is often insufficiently emphasized in studies. This study aimed to assess the incidence of HBV and pretreatment screening rates in patients with solid organ tumors at our center.
methodsWe included patients aged over 18 years who were treated for solid organ tumors at our center between January 2016 and January 2022. Data on age, sex, histopathological diagnosis, and serological parameters were retrospectively collected. Appropriate HBV screening was defined as the assessment of HBsAg, anti-HBs, and anti-HBc IgG levels prior to the initiation of immunosuppressive therapy.
resultsIn our study, HBsAg testing was requested for 13.3% of the patients, and anti-HCV testing was requested for 13.3%. Among the patients screened for HBV and HCV, the prevalence rates of HBV and HCV infection were 3.3% and 1%, respectively.
conclusionsOur findings reveal inadequate screening rates for HBV and HCV among patients receiving immunosuppressive therapy. Increasing awareness about screening and implementing regular educational programs are crucial to protect patients from reactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.